(Bloomberg) -- Biogen Inc. lost its appeals court bid to revive a key patent on the blockbuster multiple sclerosis drug Tecfidera, which accounted for more than a quarter of the company’s revenue before generic versions eroded its market share.

A trial court was correct when it invalidated a patent on the medicine, the U.S. Court of Appeals for the Federal Circuit ruled.

©2021 Bloomberg L.P.